Identification of novel urinary biomarkers for predicting renal prognosis in patients with type 2 diabetes by glycan profiling in a multicenter prospective cohort study: U-CARE study 1

Diabetes Care

Volumn 41, Issue 8, 2018, Pages 1765-1775

  Mise, Koki ^a   Imamura, Mariko ^a   Yamaguchi, Satoshi ^a   Teshigawara, Sanae ^a   Tone, Atsuhito ^b   Uchida, Haruhito A ^a   Eguchi, Jun ^a   Nakatsuka, Atsuko ^a   Ogawa, Daisuke ^a   Yoshida, Michihiro ^b   Yamada, Masao ^c   Shikata, Kenichi ^b   Wada, Jun ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c GlycoTechnica Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCAN DERIVATIVE; N ACETYLGALACTOSAMINE; PLANT LECTIN; POLYSACCHARIDE;

ADULT; AGARICUS BISPORUS; ALBUMINURIA; AMARANTHUS CAUDATUS; ARTOCARPUS HETEROPHYLLUS; CLINICAL OUTCOME; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DOLICHOS; DOLICHOS BIFLORUS; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLYCOSYLATION; HAZARD RATIO; HEMODIALYSIS; HUMAN; LECTIN BINDING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RICINUS COMMUNIS; SAMBUCUS NIGRA; URINARY EXCRETION; URINE LEVEL; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; URINALYSIS; URINE;

AGED; ALBUMINURIA; BIOMARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYSACCHARIDES; PROGNOSIS; RENAL DIALYSIS; URINALYSIS;

EID: 85053544001     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0030     Document Type: Conference Paper

References (40)

1. Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515
2. Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23:516-524
3. Fufaa GD, Weil EJ, Nelson RG, et al.; Chronic Kidney Disease Biomarkers Consortium Investigators. Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 2015; 58:188-198
4. Nowak N, Skupien J, Niewczas MA, et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 2016; 89:459-467
5. Nadkarni GN, Rao V, Ismail-Beigi F, et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: the ACCORD trial. Clin J Am Soc Nephrol 2016; 11:1343-1352
6. Foster MC, Inker LA, Hsu CY, et al.; CKD Biomarkers Consortium. Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes. Am J Kidney Dis 2015; 66:75-83
7. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323-334
8. Mann JFE, Ørsted DD, Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomesin type 2 diabetes. N Engl J Med 2017; 377:839-848
9. Mise K, Hoshino J, Ueno T, et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev 2015; 31:572-581
10. Ohtsubo K, Chen MZ, Olefsky JM, Marth JD. Pathway to diabetes through attenuation of pancreatic beta cell glycosylation and glucose transport. Nat Med 2011; 17:1067-1075
11. Gellai R, Hodrea J, Lenart L, et al. Role of O-linked N-acetylglucosamine modification in diabetic nephropathy. Am J Physiol Renal Physiol 2016; 311:F1172-F1181
12. Ravidà A, Musante L, Kreivi M, et al. Glycosylation patterns of kidney proteins differ in rat diabetic nephropathy. Kidney Int 2015; 87:963-974
13. Kuno A, Uchiyama N, Koseki-Kuno S, et al. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2005; 2:851-856
14. Inoue K, Wada J, Eguchi J, et al. Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray. PLoS One 2013; 8:e77118
15. Testa R, Vanhooren V, Bonfigli AR, et al. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One 2015; 10:e0119983
16. Bermingham ML, Colombo M, McGurnaghan SJ, et al.; SDRN Type 1 Bioresource Investigators. N-glycan profile and kidney disease in type 1 diabetes. Diabetes Care 2018; 41:79-87
17. Seino Y, Nanjo K, Tajima N, et al.; Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1:212-228
18. Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19-62
19. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev 2013; 42:4443-4458
20. Safina G. Application of surface plasmon resonance for the detection of carbohydrates, glycoconjugates, and measurement of the carbohydrate-specific interactions: a comparison with conventional analytical techniques. A critical review. Anal Chim Acta 2012; 712: 9-29
21. Cheng CI, Chang YP, Chu YH. Biomolecular interactions and tools for their recognition: focus on the quartz crystal microbalance and its diverse surface chemistries and applications. Chem Soc Rev 2012; 41:1947-1971
22. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 2010; 56:32-38
23. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012; 3:39-40
24. Fong DS, Aiello L, Gardner TW, et al.; American Diabetes Association. Retinopathy in diabetes. Diabetes Care 2004; 27(Suppl. 1):S84-S87
25. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589
26. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563-2569
27. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172; discussion 207-112
28. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21
29. Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176:473-481
30. Mise K, Hoshino J, Ueno T, et al. Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-d-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. Clin J Am Soc Nephrol 2016; 11:593-601
31. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014; 85:49-61
32. Gill DJ, Clausen H, Bard F. Location, location, location: new insights into O-GalNAc protein glycosylation. Trends Cell Biol 2011; 21:149-158
33. Belický Š, Katrlík J, Tkáč J. Glycan and lectin biosensors. Essays Biochem 2016; 60:37-47
34. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin-the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984; 98:1591-1596
35. Dekan G, Gabel C, Farquhar MG. Sulfate contributes to the negative charge of podocalyxin, the major sialoglycoprotein of the glomerular filtration slits. Proc Natl Acad Sci U S A 1991; 88: 5398-5402
36. Gelberg H, Healy L, Whiteley H, Miller LA, Vimr E. In vivo enzymatic removal of alpha 2->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury. Lab Invest 1996; 74: 907-920
37. Song K, Fu J, Song J, et al. Loss of mucin-type O-glycans impairs the integrity of the glomerular filtration barrier in the mouse kidney. J Biol Chem 2017; 292:16491-16497
38. Holthöfer H, Pettersson E, Törnroth T. Diabetes mellitus associated changes in glomerular glycocompounds: a fluorescence microscopical study. Histochem J 1987; 19:351-356
39. Truong LD, Phung VT, Yoshikawa Y, Mattioli CA. Glycoconjugates in normal human kidney. A histochemical study using 13 biotinylated lectins. Histochemistry 1988; 90:51-60
40. Ruhaak LR, Uh HW, Beekman M, et al. Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity. PLoS One 2010; 5:e12566